arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Akebia Therapeutics, Inc.

AKBA
$0.91 ▼ -0.04 (-4.34%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

Akebia Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $243.0M
Dividend Yield
Revenue Growth -6.6%
Op. Margin -8.8%
ROIC -6.2%
FCF / Share $-0.08
Trailing P/E
Price / Book 8.9x
FCF Yield
Debt / Equity 1.79
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.54M
↓ -6.6%
Net Income Profit after all expenses
$-9.05M
↑ +26.1%
Operating Margin Operating profit as % of sales
-8.8%
↑ +40.9% 56th
FCF / Share Free cash flow per share
$-0.08
↓ -37.9%
Long-Term Debt Long-term obligations
$48.89M
↑ +1.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
58
Returns
29
Financial Health
44
Cash Quality
1

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters